Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
- Registration Number
- NCT02278588
- Lead Sponsor
- State University of New York at Buffalo
- Brief Summary
In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description PD-R Rasagiline Parkinson's disease receiving rasagiline
- Primary Outcome Measures
Name Time Method Change in cognitive biomarkers assessed by DTI 2.5 years Comparison of change in cognitive biomarkers with change in MMSE and MoCA scores 2.5 years
- Secondary Outcome Measures
Name Time Method Comparison of Baseline plasma BDNF with magnitude of change in brain cognitive biomarkers and MMSE and MoCA scores 2.5 years Comparison of changes in plasma BDNF with changes in brain cognitive biomarkers and MMSE and MoCA scores 2.5 years
Trial Locations
- Locations (1)
University at Buffalo
🇺🇸Buffalo, New York, United States